Under the Global Vaccine Action Plan, measles and rubella are targeted for elimination in 5 WHO Regions by 2020. WHO is the lead technical agency responsible for coordination of immunization and surveillance activities supporting all countries to achieve this goal.
Transmitted in airborne droplets when infected people sneeze or cough, rubella is an acute, usually mild viral disease traditionally affecting susceptible children and young adults worldwide. Rubella infection just before conception and in early pregnancy may result in miscarriage, foetal death or congenital defects known as congenital rubella syndrome (CRS). The highest risk of CRS is found in countries with high rates of susceptibility to rubella among women of childbearing age.
In 1996, an estimated 22 000 babies were born with CRS in Africa, an estimated 46 000 in South-East Asia and close to 13 000 in the Western Pacific. Very few countries in these regions had introduced rubella-containing vaccine by the year 2008, and therefore the current burden of CRS in these settings is thought to be similar to that estimated for 1996.
Rubella vaccines are available either in monovalent formulation or in combinations with other vaccine viruses, as rubella-containing vaccines (RCVs). Commonly used RCVs are combinations with vaccines against measles (MR), measles and mumps (MMR), or measles, mumps and varicella (MMRV).
Large-scale rubella vaccination during the last decade has drastically reduced or practically eliminated rubella and CRS in many developed and in some developing countries. Indeed, the western hemisphere and several European countries have eliminated rubella and CRS.
WHO recommends that countries take the opportunity of accelerated measles control and elimination activities to introduce rubella-containing vaccines. All countries that have not yet introduced rubella vaccine, and are providing two doses of measles vaccine using routine immunization and/or supplementary immunization activities should consider the inclusion of RCV in their immunization programme.
WHO position papers
Rubella vaccines - in English and French versions (July 2011)
- Full list of WHO position papers on vaccines and accompanying documents
- Immunization schedules
Disease burden and surveillance
- Introducing Rubella Vaccine into National Immunization Programmes
- Global Measles and Rubella Strategic Plan 2012-2020
Framework for verifying elimination of measles and rubella
- WHO health topic: Rubella
- Measles and Rubella Initiative
MRI annual report 2013
- Schedule of upcoming Measles and Rubella supplementary immunization activities
Last updated: 17 August 2015